Business Context and Reporting Period
This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on June 21, 2017. The report details a significant corporate event regarding the Company's partnership with Shire.
Key Financial Metrics
The filing does not provide specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The document focuses exclusively on a regulatory milestone and the resulting royalty agreement structure.
Material Changes
The primary material event is the U.S. Food and Drug Administration (FDA) approval of Mydayis, a once-daily treatment for Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 13 and older. This approval was granted to the Company's partner, Shire. Under the existing agreement, Shire is obligated to pay Supernus a single-digit percentage royalty on net sales of the product.
Guidance, Outlook, and Risks
- Commercial Availability: Shire expects to make Mydayis commercially available in the United States in the third quarter of 2017.
- Revenue Model: Supernus's financial benefit from this product is contingent on net sales generated by Shire, subject to the single-digit royalty rate.
- Risks: The filing does not explicitly list new risks, though reliance on a partner for commercialization and royalty collection is inherent to the business model described.
Investor Verification Checklist
- Verify the specific single-digit royalty percentage defined in the agreement with Shire.
- Confirm the actual commercial launch date of Mydayis in Q3 2017.
- Monitor future filings for initial sales data and royalty payments received from Shire.
- Review the full text of the press release (Exhibit 99.1) for additional details on the product's market positioning.